Literature DB >> 11788680

Intensive, long-term plasma exchange therapy for severe hypertriglyceridemia in acquired generalized lipoatrophy.

Charles Bolan1, Elif Arioglu Oral, Phillip Gorden, Simeon Taylor, Susan F Leitman.   

Abstract

We report dramatic improvement in clinical and laboratory parameters after intensive plasma exchange therapy in a 15-yr-old girl with acquired generalized lipoatrophy and refractory hypertriglyceridemia. One hundred and twenty-five procedures were performed over 720 d. Two or three plasma volumes were exchanged per procedure, using peripheral venous access and albumin as replacement solution. Regression of painful cutaneous xanthomata and reduction in massive hepatomegaly were noted within the first two procedures. Triglyceride levels started at 109 mmol/liter (9670 mg/dl) and decreased acutely by 60-85%/procedure. Lipid removal averaged 83 g/procedure and was highly correlated with preexchange lipid levels. Lipid levels rebounded to baseline values within 7 d after exchange and appeared to rebound more rapidly after larger exchanges. Maximum benefit was achieved with weekly 1.5- to 2.0-volume exchanges. No significant decrease in apolipoprotein CII levels was detected after plasma exchange regardless of the volume of exchange; however, other plasma factors regulating triglyceride synthesis or clearance may have been removed during the procedures. Plasma exchange was well tolerated, without clinical, immunological, or hormonal deterioration. These data indicate that intensive plasma exchange therapy over a protracted time may produce sustained benefit in patients with severe, symptomatic hypertriglyceridemia refractory to standard medical therapy.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11788680     DOI: 10.1210/jcem.87.1.8176

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  4 in total

Review 1.  Lipoatrophic diabetes and other related syndromes.

Authors:  Elif Arioglu Oral
Journal:  Rev Endocr Metab Disord       Date:  2003-03       Impact factor: 6.514

2.  The clinical approach to the detection of lipodystrophy - an AACE consensus statement.

Authors:  Yehuda Handelsman; Elif A Oral; Zachary T Bloomgarden; Rebecca J Brown; Jean L Chan; Daniel Einhorn; Alan J Garber; Abhimanyu Garg; W Timothy Garvey; George Grunberger; Robert R Henry; Norman Lavin; Carmen D Tapiador; Christian Weyer
Journal:  Endocr Pract       Date:  2013 Jan-Feb       Impact factor: 3.443

3.  A Novel Generalized Lipodystrophy-Associated Progeroid Syndrome Due to Recurrent Heterozygous LMNA p.T10I Mutation.

Authors:  Iram Hussain; Nivedita Patni; Masako Ueda; Ekaterina Sorkina; Cynthia M Valerio; Elaine Cochran; Rebecca J Brown; Joseph Peeden; Yulia Tikhonovich; Anatoly Tiulpakov; Sarah R S Stender; Elisabeth Klouda; Marwan K Tayeh; Jeffrey W Innis; Anders Meyer; Priti Lal; Amelio F Godoy-Matos; Milena G Teles; Beverley Adams-Huet; Daniel J Rader; Robert A Hegele; Elif A Oral; Abhimanyu Garg
Journal:  J Clin Endocrinol Metab       Date:  2018-03-01       Impact factor: 5.958

Review 4.  The Diagnosis and Management of Lipodystrophy Syndromes: A Multi-Society Practice Guideline.

Authors:  Rebecca J Brown; David Araujo-Vilar; Pik To Cheung; David Dunger; Abhimanyu Garg; Michelle Jack; Lucy Mungai; Elif A Oral; Nivedita Patni; Kristina I Rother; Julia von Schnurbein; Ekaterina Sorkina; Takara Stanley; Corinne Vigouroux; Martin Wabitsch; Rachel Williams; Tohru Yorifuji
Journal:  J Clin Endocrinol Metab       Date:  2016-10-06       Impact factor: 5.958

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.